Literature DB >> 22901340

Directed evolution reveals requisite sequence elements in the functional expression of P450 2F1 in Escherichia coli.

James B Y H Behrendorff1, Chad D Moore, Keon-Hee Kim, Dae-Hwan Kim, Christopher A Smith, Wayne A Johnston, Chul-Ho Yun, Garold S Yost, Elizabeth M J Gillam.   

Abstract

Cytochrome P450 2F1 (P450 2F1) is expressed exclusively in the human respiratory tract and is implicated in 3-methylindole (3MI)-induced pneumotoxicity via dehydrogenation of 3MI to a reactive electrophilic intermediate, 3-methyleneindolenine (3-MEI). Studies of P450 2F1 to date have been limited by the failure to express this enzyme in Escherichia coli. By contrast, P450 2F3, a caprine homologue that shares 84% sequence identity with P450 2F1 (86 amino acid differences), has been expressed in E. coli at yields greater than 250 nmol/L culture. We hypothesized that a limited number of sequence differences between P450s 2F1 and 2F3 could limit P450 2F1 expression in E. coli and that problematic P450 2F1 sequence elements could be identified by directed evolution. A library of P450 2F1/2F3 mutants was created by DNA family shuffling and screened for expression in E. coli. Three generations of DNA shuffling revealed a mutant (named JH_2F_F3_1_007) with 96.5% nucleotide sequence identity to P450 2F1 and which expressed 119 ± 40 pmol (n = 3, mean ± SD) hemoprotein in 1 mL microaerobic cultures. Across all three generations, two regions were observed where P450 2F3-derived sequence was consistently substituted for P450 2F1 sequence in expressing mutants, encoding nine amino acid differences between P450s 2F1 and 2F3: nucleotides 191-278 (amino acids 65-92) and 794-924 (amino acids 265-305). Chimeras constructed to specifically test the importance of these two regions confirmed that P450 2F3 sequence is essential in both regions for expression in E. coli but that other non-P450 2F1 sequence elements outside of these regions also improved the expression of mutant JH_2F_F3_1_007. Mutant JH_2F_F3_1_007 catalyzed the dehydrogenation of 3MI to 3-MEI as indicated by the observation of glutathione adducts after incubation in the presence of glutathione. The JH_2F_F3_1_007 protein differs from P450 2F1 at only 20 amino acids and should facilitate further studies of the structure-activity relationships of P450s of the 2F subfamily.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22901340      PMCID: PMC3466110          DOI: 10.1021/tx300281g

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  47 in total

1.  Drug metabolism by Escherichia coli expressing human cytochromes P450.

Authors:  A Parikh; E M Gillam; F P Guengerich
Journal:  Nat Biotechnol       Date:  1997-08       Impact factor: 54.908

2.  DNA shuffling of a family of genes from diverse species accelerates directed evolution.

Authors:  A Crameri; S A Raillard; E Bermudez; W P Stemmer
Journal:  Nature       Date:  1998-01-15       Impact factor: 49.962

3.  Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in Escherichia coli.

Authors:  K Nishihara; M Kanemori; M Kitagawa; H Yanagi; T Yura
Journal:  Appl Environ Microbiol       Date:  1998-05       Impact factor: 4.792

4.  DNA shuffling of cytochrome P450 enzymes.

Authors:  James B Y H Behrendorff; Wayne A Johnston; Elizabeth M J Gillam
Journal:  Methods Mol Biol       Date:  2013

5.  Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole.

Authors:  G L Skiles; G S Yost
Journal:  Chem Res Toxicol       Date:  1996 Jan-Feb       Impact factor: 3.739

6.  Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells.

Authors:  D L Lanza; E Code; C L Crespi; F J Gonzalez; G S Yost
Journal:  Drug Metab Dispos       Date:  1999-07       Impact factor: 3.922

7.  Formation of indigo by recombinant mammalian cytochrome P450.

Authors:  E M Gillam; A M Aguinaldo; L M Notley; D Kim; R G Mundkowski; A A Volkov; F H Arnold; P Soucek; J J DeVoss; F P Guengerich
Journal:  Biochem Biophys Res Commun       Date:  1999-11-19       Impact factor: 3.575

8.  Cloning and expression of CYP2F3, a cytochrome P450 that bioactivates the selective pneumotoxins 3-methylindole and naphthalene.

Authors:  H Wang; D L Lanza; G S Yost
Journal:  Arch Biochem Biophys       Date:  1998-01-15       Impact factor: 4.013

9.  Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450.

Authors:  T Nakajima; E Elovaara; F J Gonzalez; H V Gelboin; H Raunio; O Pelkonen; H Vainio; T Aoyama
Journal:  Chem Res Toxicol       Date:  1994 Nov-Dec       Impact factor: 3.739

10.  Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding.

Authors:  J Thornton-Manning; M L Appleton; F J Gonzalez; G S Yost
Journal:  J Pharmacol Exp Ther       Date:  1996-01       Impact factor: 4.030

View more
  3 in total

1.  Structure-Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6.

Authors:  Tsutomu Shimada; Shigeo Takenaka; Kensaku Kakimoto; Norie Murayama; Young-Ran Lim; Donghak Kim; Maryam K Foroozesh; Hiroshi Yamazaki; F Peter Guengerich; Masayuki Komori
Journal:  Chem Res Toxicol       Date:  2016-05-12       Impact factor: 3.739

Review 2.  Reductive Cytochrome P450 Reactions and Their Potential Role in Bioremediation.

Authors:  James B Y H Behrendorff
Journal:  Front Microbiol       Date:  2021-04-15       Impact factor: 5.640

3.  Human CYP2A13 and CYP2F1 Mediate Naphthalene Toxicity in the Lung and Nasal Mucosa of CYP2A13/2F1-Humanized Mice.

Authors:  Lei Li; Sarah Carratt; Matthew Hartog; Nataliia Kovalchik; Kunzhi Jia; Yanan Wang; Qing-Yu Zhang; Patricia Edwards; Laura Van Winkle; Xinxin Ding
Journal:  Environ Health Perspect       Date:  2017-06-08       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.